Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
REVENUES:    
Product revenue, net $ 2,482
COSTS AND EXPENSES:    
Cost of sales 1,660
Research and development 12,863 26,511
General and administrative 9,310 7,391
Total operating expenses 23,833 33,902
Operating loss (21,351) (33,902)
Gain on change in fair value of warrant liabilities 7,005
Other (expense) income, net (593) 897
Net loss available to common stockholders $ (14,939) $ (33,005)
Net loss per common share, basic $ (0.18) $ (3.21)
Net loss per common share, diluted $ (0.18) $ (3.21)
Weighted average common shares outstanding, basic 80,879,108 10,268,500
Weighted average common shares outstanding, diluted 80,879,108 10,268,500